Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.09M Sell
5,234
-117
-2% -$26K 0.1% 86
2025
Q4
$1.18M Sell
5,351
-494
-8% -$113K 0.1% 86
2025
Q3
$1.37M Buy
5,845
+1,063
+22% +$216K 0.12% 79
2025
Q2
$912K Hold
4,782
0.09% 82
2025
Q1
$1M Sell
4,782
-3
-0.1% -$583 0.11% 77
2024
Q4
$850K Sell
4,785
-1
-0% -$184 0.09% 81
2024
Q3
$945K Sell
4,786
-96
-2% -$17.9K 0.1% 83
2024
Q2
$837K Sell
4,882
-2,545
-34% -$422K 0.09% 88
2024
Q1
$1.35M Buy
7,427
+8
+0.1% +$1.38K 0.12% 81
2023
Q4
$1.11M Hold
7,419
0.12% 79
2023
Q3
$1.11M Buy
7,419
+59
+0.8% +$8.66K 0.12% 79
2023
Q2
$992K Sell
7,360
-10
-0.1% -$1.47K 0.11% 81
2023
Q1
$1.17M Hold
7,370
0.14% 70
2022
Q4
$1.19M Buy
7,370
+8
+0.1% +$1.23K 0.15% 69
2022
Q3
$988K Buy
7,362
+2,999
+69% +$430K 0.15% 60
2022
Q2
$668K Buy
4,363
+245
+6% +$37.4K 0.1% 66
2022
Q1
$668K Buy
4,118
+161
+4% +$23.4K 0.1% 56
2021
Q4
$536K Buy
+3,957
New +$467K 0.08% 61
2020
Q2
Sell
-268
Closed -$20K 67
2020
Q1
$20K Sell
268
-949
-78% -$80.8K 0.01% 137
2019
Q4
$108K Buy
1,217
+800
+192% +$66.4K 0.02% 75
2019
Q3
$32K Hold
417
0.01% 117
2019
Q2
$30K Sell
417
-34
-8% -$2.67K 0.01% 113
2019
Q1
$36K Buy
451
+34
+8% +$2.78K 0.01% 99
2018
Q4
$38K Buy
+417
New +$36.7K 0.01% 96

Other funds holding ABBV

Salomon & Ludwin's ABBV Position: Q1 2026 in Review

Salomon & Ludwin reduced its AbbVie (ABBV) stake by 2.2% in Q1 2026, selling an estimated $26K and leaving 5,234 shares worth $1.09M. The position accounts for 0.1% of the portfolio, ranked #86.

Salomon & Ludwin first reported a position in ABBV in Q4 2018 and has held it in 24 quarters since. The position peaked at $1.37M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Salomon & Ludwin held 5,234 shares of AbbVie worth $1.09M as of Q1 2026.
  • Salomon & Ludwin sold 117 AbbVie shares in Q1 2026, an estimated $26K.
  • AbbVie made up 0.1% of Salomon & Ludwin's portfolio in Q1 2026, its #86 holding.
  • Salomon & Ludwin first reported a position in AbbVie in Q4 2018 and has held it in 24 quarters since.
  • Salomon & Ludwin's AbbVie position peaked at $1.37M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.